The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Atypical antipsychotics for aggression and psychosis in Alzheimer's disease
Open accessAbstract
BACKGROUND: Aggression, agitation or psychosis occur in the majority of people with dementia at some point in the illness. There have been a number of trials of atypical antipsychotics to treat these symptoms over the last five years, and a systematic review is needed to evaluate the evidence in a balanced way. OBJECTIVES: To determine whether evidence supports the use of atypical antipsychotics for the treatment of aggression, agitation and psychosis in people with Alzheimer's disease. SEARCH STRATEGY: The trials were identified from a last updated search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 7 December 2004 using the terms olanzapine, quetiapine, risperidone, clozapine, amisulpride, sertindole, zotepine, aripiprazole, ziprasidone. This Register contains articles from all major healthcare databases and many ongoing trials databases and is updated regularly. SELECTION CRITERIA: Randomised, placebo-controlled trials, with concealed allocation, where dementia and psychosis and/or aggression were assessed. DATA COLLECTION AND ANALYSIS: 1. Two reviewers extracted data from included trials2. Data were pooled where possible, and analysed using appropriate statistical methods3. Analysis included patients treated with an atypical antipsychotic, compared with placebo MAIN RESULTS: Sixteen placebo controlled trials have been completed with atypical antipsychotics although only nine had sufficient data to contribute to a meta-analysis and only five have been published in full in peer reviewed journals. No trials of amisulpiride, sertindole or zotepine were identified which met the criteria for inclusion. The included trials led to the following results:1. There was a significant improvement in aggression with risperidone and olanzapine treatment compared to placebo.2. There was a significant improvement in psychosis amongst risperidone treated patients.3. Risperidone and olanzpaine treated patients had a significantly higher incidence of serious adverse cerebrovascular events (including stroke), extra-pyramidal side effects and other important adverse outcomes.4. There was a significant increase in drop-outs in risperidone (2 mg) and olanzapine (5-10 mg) treated patients.5. The data were insufficient to examine impact upon cognitive function. AUTHORS' CONCLUSIONS: Evidence suggests that risperidone and olanzapine are useful in reducing aggression and risperidone reduces psychosis, but both are associated with serious adverse cerebrovascular events and extra-pyramidal symptoms. Despite the modest efficacy, the significant increase in adverse events confirms that neither risperidone nor olanzapine should be used routinely to treat dementia patients with aggression or psychosis unless there is marked risk or severe distress. Although insufficient data were available from the considered trials, a meta-analysis of seventeen placebo controlled trials of atypical neuroleptics for the treatment of behavioural symptoms in people with dementia conducted by the Food and Drug Administration (using data not in the public domain) suggested a significant increase in mortality (OR 1.7).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Diagnostic and Statistical Manual of Mental Disorders
(2018) · The SAGE Encyclopedia of Educational Research, Measurement, and Evaluation · doi:10.4135/9781506326139.n198 · Cited by 1,230
(1987) · PubMed · Cited by 1,147
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
The Impact of Dementia on the Family
Rabins, P. V. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03330030039022 · Cited by 755
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.8.1049 · Cited by 744
Katz, I. R., Jeste, D. V., Mintzer, J. E., Clyde, C., Napolitano, J., Brecher, M., & The Risperidone Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0207 · Cited by 741
A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia
Schneider, L. S., Pollock, V. E., & Lyness, S. A. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb02407.x · Cited by 650
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
Neuroleptic sensitivity in patients with senile dementia of Lewy body type.
McKeith, I., Fairbairn, A., Perry, R., Thompson, P., & Perry, E. (1992) · BMJ · doi:10.1136/bmj.305.6855.673 · Cited by 624
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
De Deyn, P. P., Rabheru, K., Rasmussen, A., Bocksberger, J. P., Dautzenberg, P. L. J., Eriksson, S., & Lawlor, B. A. (1999) · Neurology · doi:10.1212/wnl.53.5.946 · Cited by 615
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Reilly, J., Ayis, S., Ferrier, I., Jones, S., & Thomas, S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02035-3 · Cited by 602
Street, J. S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.968 · Cited by 590
Brodaty, H., Ames, D., Snowdon, J., Woodward, M., Kirwan, J., Clarnette, R., Lee, E., Lyons, B., & Grossman, F. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0205 · Cited by 464
Ballard, C., Margallo-Lana, M., Juszczak, E., Douglas, S., Swann, A., Thomas, A., O'Brien, J., Everratt, A., Sadler, S., Maddison, C., et al. (2005) · BMJ · doi:10.1136/bmj.38369.459988.8f · Cited by 315
Self-citationSchneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Ferris, S. H., Schmitt, F. A., Grundman, M., & Thomas, R. G. (1997) · Alzheimer Disease · doi:10.1007/978-1-4612-4116-4_64 · Cited by 303
Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up
McShane, R., Keene, J., Gedling, K., Fairburn, C., Jacoby, R., & Hope, T. (1997) · BMJ · doi:10.1136/bmj.314.7076.266 · Cited by 267
Huppert, F. A., Brayne, C., Gill, C., Paykel, E. S., & Beardsall, L. (1995) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1995.tb01487.x · Cited by 262
Haloperidol for agitation in dementia
Lonergan, E., Luxenberg, J., Colford, J. M., & Birks, J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002852 · Cited by 212
Self-citationSchneider, L. S., Tariot, P. N., Lyketsos, C. G., Dagerman, K. S., Davis, K. L., Davis, S., Hsiao, J. K., Jeste, D. V., Katz, I. R., Olin, J. T., et al. (2001) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00004 · Cited by 211
Meehan, K. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00365-7 · Cited by 198
De Deyn, P. P., Carrasco, M. M., Deberdt, W., Jeandel, C., Hay, D. P., Feldman, P. D., Young, C. A., Lehman, D. L., & Breier, A. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1032 · Cited by 198
Cohen-Mansfield, J. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297003530 · Cited by 196
Ballard, C., O'Brien, J., James, I., Mynt, P., Lana, M., Potkins, D., Reichelt, K., Lee, L., Swann, A., & Fossey, J. (2001) · International Psychogeriatrics · doi:10.1017/s1041610201007499 · Cited by 173
Self-citationAripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease
Deyn, P. P. D., Jeste, D. V., Swanink, R., Kostic, D., Breder, C. D., Carson, W. H., & Iwamoto, T. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000178415.22309.8f · Cited by 150
Deberdt, W. G., Dysken, M. W., Rappaport, S. A., Feldman, P. D., Young, C. A., Hay, D. P., Lehman, D. L., Dossenbach, M. R. K., Degenhardt, E. K., & Breier, A. F. (2005) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200508000-00012 · Cited by 129
Long-term use of quetiapine in elderly patients with psychotic disorders
Tariot, P. N., Salzman, C., Yeung, P. P., Pute, J., & Rak, I. W. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80085-5 · Cited by 128
Chan, W. C., Lam, L. C. W., Choy, C. N. P., Leung, V., Li, S.-W., & Chiu, H. F. K. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.504 · Cited by 119
Hallucinations and associated factors in Alzheimer's disease
Gilley, D. W., Whalen, M. E., Wilson, R. S., & Bennett, D. A. (1991) · Journal of Neuropsychiatry · doi:10.1176/jnp.3.4.371 · Cited by 113
Clark, W. S., Street, J. S., Feldman, P. D., & Breier, A. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0108 · Cited by 101
Medication use in nursing homes for elderly people
Furniss, L., Craig, S. K. L., & Burns, A. S. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199807)13:7<433::aid-gps798>3.0.co;2-9 · Cited by 93
Beuzen, J. N., Taylor, N. F., Wesnes, K. A., & Wood, A. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300207 · Cited by 89
Street, J. S., Clark, W. S., Kadam, D. L., Mitan, S. J., Juliar, B. E., Feldman, P. D., & Breier, A. F. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200112)16:1+<::aid-gps569>3.0.co;2-j · Cited by 84
Treating behavioural and psychological signs in Alzheimer's disease
Ballard, C. G., & O'Brien, J. T. (1999) · BMJ · doi:10.1136/bmj.319.7203.138 · Cited by 76
Self-citationA follow up study of depression in the carers of dementia sufferers: Table 1
Ballard, C. G., Eastwood, C., Gahir, M., & Wilcock, G. K. (1996) · BMJ · doi:10.1136/bmj.312.7036.947 · Cited by 71
Self-citationFontaine, C. S., Hynan, L. S., Koch, K., Martin‐Cook, K., Svetlik, D. A., & Weiner, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0617 · Cited by 64
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's Disease Trial
Schneider, L. S. S., Ismail, M. S., Dagerman, K., Davis, S. M., Olin, J. T., McManus, D., Pfeiffer, E., Ryan, J. M., Sultzer, D. L., & Tariot, P. N. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006991 · Cited by 59
Risperidone is Effective for Wandering and Disturbed Sleep/Wake Patterns in Alzheimer’s Disease
Meguro, K., Meguro, M., Tanaka, Y. R., Akanuma, K., Yamaguchi, K., & Itoh, M. (2004) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704264535 · Cited by 57
Efficacy of atypical antipsychotics in elderly patients with dementia.
Tariot, P. N., Profenno, L. A., & Ismail, M. S. (2004) · PubMed · Cited by 52
Psychosis of Alzheimer Disease: Validity of the Construct and Response to Risperidone
Schneider, L. S. S., Katz, I. R., Park, S., Napolitano, J. A., Martínez, R. A., & Azen, S. P. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200307000-00004 · Cited by 50
A Structured Trial of Risperidone for the Treatment of Agitation in Dementia
Lavretsky, H., & Sultzer, D. L. (1998) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199805000-00006 · Cited by 48
Neuroleptic Drugs in the Management of Behavioral Symptoms of Alzheimer’s Disease
Tune, L. E., Steele, C., & Cooper, T. (1991) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30312-5 · Cited by 47
Weiser, M., Rotmensch, H. H., Korczyn, A. D., Hartman, R. D., Cicin-Sain, A., & Anand, R. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.599 · Cited by 46
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability
Williams, H., Clarke, R., Bouras, N., Martin, J., & Holt, G. (2000) · Journal of Intellectual Disability Research · doi:10.1046/j.1365-2788.2000.00284.x · Cited by 45
Davis, S. M., Koch, G. G., DAVIS, C. E., & LaVange, L. M. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006993 · Cited by 44
Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis
Mintzer, J. E., Faison, W. E., Street, J. S., Sutton, V. K., & Breier, A. F. (2001) · International Journal of Geriatric Psychiatry · Cited by 40
Psychotic symptoms, aggression and restlessness in dementia
Ballard, C. G., Gray, A., & Ayre, G. (1999) · PubMed · doi:10.25405/ncl.34661118 · Cited by 38
Self-citationRisperidone for the Treatment of Behavioral Disturbances in Dementia: A Case Series
Herrmann, N., Tourigny-Rivard, M.-F., Flynn, M., Ward, C., Rabheru, K., & Campbell, B. I. (1998) · Journal of Neuropsychiatry · doi:10.1176/jnp.10.2.220 · Cited by 38
Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers
Allain, H., Tessier, C., Bentué‐Ferrer, D., Tarral, A., Breton, S. L., Gandon, J. M., & Bouhours, P. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1272-2 · Cited by 33
Rabinowitz, J., Katz, I. R., Deyn, P. P. D., Brodaty, H., Greenspan, A. J., & Davidson, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1006 · Cited by 31
Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.
Mintzer, J. E. (2001) · PubMed · Cited by 31
Antipsychotic Agents in Patients with Dementia
Defilippi, J. L., & Crismon, M. L. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.1.23.34661 · Cited by 30
Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia
Katz, I. R., Brecher, M., Clyde, C., & Napolitano, J. A. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(97)88668-9 · Cited by 12
Olanzapine in whole, not half, tablets for psychosis from Alzheimer’s dementia
Wolfgang, S. A. (1999) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/56.21.2245 · Cited by 12
Antipsychotic Treatment in Outpatients With Dementia
Devanand, D. P. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297003621 · Cited by 11
Brecher, M., Okamoto, A., Napolitano, J. A., & Kane, J. M. (1999) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199911001-00115 · Cited by 9
Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disease
Street, J. S., Clark, W. S., Gannon, K. S., Mitan, S. J., Kadam, D. L., Sanger, T., Tamura, R., & Tollefson, G. D. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)80470-2 · Cited by 7
Brecher, M. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)80511-7 · Cited by 6
Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil
Parsa, M. A., Poggi, E., & Barte, L. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80339-9 · Cited by 6
P1-330 Flexible-dose aripiprazole in psychosis of Alzheimer's disease
Streim, J. E., Breder, C. D., Swanink, R., McQuade, R. D., Iwamoto, T., Carson, W. H., & Stock, E. G. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80643-2 · Cited by 6
Street, J. S., Clark, W. S., Juliar, B. E., Feldman, P. D., Kadam, D. L., & Breier, A. F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00802-7 · Cited by 4
Clark, W. S., Street, J. S., Gaimon, K. S., Sanger, T., Tollefson, G. D., & Breier, A. F. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)80472-6 · Cited by 3
P1-326 Dose-ranging study of aripiprazole in patients with dementia of Alzheimer's disease
Breder, C. D., Swanink, R., Marcus, R. N., Kostic, D., Iwamoto, T., Carson, W. H., & McQuade, R. D. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80639-0 · Cited by 3
Clark, W. S., Street, J. S., Sanger, T. M., & Breier, A. F. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83424-7 · Cited by 3
Reduction of psychotic symptoms in patients with Lewy Body-like symptoms treated with olanzapine
Street, J. S., Clark, W. S., Gannon, K. S., Sanger, T. M., & Breier, A. F. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)80471-4 · Cited by 2
Clark, W. S., Street, J. S., Sanger, T. M., Feldman, P. D., & Breier, A. F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00803-9 · Cited by 2
Clark, W. S., Street, J. S., Sanger, T. M., Feldman, P. D., & Breier, A. F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00804-0 · Cited by 1
Cited by
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Adverse drug reactions in special populations – the elderly
Davies, E. A., & O'Mahony, M. S. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12596 · Cited by 604
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
Self-citationBallard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Self-citationMaher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Metadata
- Authors
- Ballard, C. G., Waite, J., & Birks, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-01-25
- Volume
- 2012
- Issue
- 5
- Pages
- CD003476-CD003476
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1948712038
- Cited by
- 525
- References
- 79
- FWCI
- 19.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.